Birgit Girshick, Chief Executive Officer and Director of Charles River Laboratories International, Inc., filed a Form 4 on August 20, 2026, reporting a disposition of 528 shares of common stock on August 19, 2026, via a gift transaction at a price of $0.
Key Highlights
- Transaction type: 528 shares of common stock disposed of under transaction code "G" (gift) at a price of $0 on August 19, 2026.
- Direct holdings after transaction: Girshick directly owns 35,485 shares of common stock following the reported transaction.
- Indirect holdings: Girshick also holds 43,803 shares indirectly through a Revocable Trust.
- Reporting person role: Girshick is identified as both a Director and Chief Executive Officer of the issuer.
- No derivative securities: Table II of the filing reports no derivative security transactions.
Girshick Gift Transaction and Beneficial Ownership at Charles River Laboratories
According to the filing, Birgit Girshick, serving as Chief Executive Officer and Director of Charles River Laboratories International, Inc. (NYSE:CRL), reported the disposition of 528 shares of common stock on August 19, 2026. The transaction was recorded under code "G," indicating a gift, at a stated price of $0. The filing does not provide additional explanation for the transaction beyond the coded designation.
Following the reported transaction, the filing discloses that Girshick directly holds 35,485 shares of Charles River Laboratories common stock. In addition, the filing reports 43,803 shares held indirectly through a Revocable Trust, bringing the total beneficial ownership across both direct and indirect forms to 79,288 shares as reflected in the filing's tables.
Table II of the filing, covering derivative securities such as options and warrants, contains no reported transactions or holdings. The Form 4 was filed by one reporting person and covers a single earliest transaction date of August 19, 2026. The filing was signed by Birgit Girshick on August 19, 2026.
What Was Disclosed
The filing reported a gift disposition of 528 shares of Charles River Laboratories common stock by CEO Birgit Girshick at $0 on August 19, 2026, leaving her with 35,485 shares held directly and 43,803 shares held indirectly via a Revocable Trust.




Please wait processing your request...